Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 19 de 19
Filtrar
1.
J Dtsch Dermatol Ges ; 22(4): 513-519, 2024 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-38483049

RESUMEN

BACKGROUND AND OBJECTIVES: Previous work has demonstrated that hydrochlorothiazide (HCTZ) is a risk factor for squamous cell carcinomas (SCC) and basal cell carcinomas (BCC) due to pro-photocarcinogenic effects. Atypical fibroxanthoma (AFX) and pleomorphic sarcoma (PDS), both ultraviolet-induced cancers, display a rare but rising cutaneous tumor entity. This study aimed to evaluate if the use of HCTZ is higher in patients with AFX/PDS than in patients with SCC/BCC and subsequently may be a risk factor for AFX/PDS-development. PATIENTS AND METHODS: In a retrospective study of four German skin cancer centers, AFX/PDS cases and SCC/BCC controls were sex and age matched (1:3) over a time-period of 7 years (2013-2019) to evaluate the use of HCTZ, immunosuppressive medication, second malignancies, and presence of diabetes mellitus. RESULTS: Overall, 146 AFX/PDS and 438 controls (SCC/BCC) were included in the study. The use of HCTZ was significantly higher in patients with AFX/PDS (44.5%) compared to patients with SCC/BCC (25.3%). Additionally, the presence of diabetes mellitus was significantly higher in AFX/PDS patients. CONCLUSIONS: This study demonstrates a significantly higher use of HCTZ in patients with AFX/PDS compared to SCC/BCC. This result suggests that HCTZ may be a risk factor for AFX/PDS. Additionally, diabetes mellitus or its comorbidities may be associated with an increased risk for AFX/PDS.


Asunto(s)
Carcinoma Basocelular , Carcinoma de Células Escamosas , Diabetes Mellitus , Histiocitoma Fibroso Maligno , Sarcoma , Neoplasias Cutáneas , Humanos , Hidroclorotiazida/efectos adversos , Estudios Retrospectivos , Neoplasias Cutáneas/inducido químicamente , Neoplasias Cutáneas/epidemiología , Neoplasias Cutáneas/complicaciones , Sarcoma/epidemiología , Sarcoma/patología , Carcinoma Basocelular/inducido químicamente , Carcinoma Basocelular/epidemiología , Carcinoma de Células Escamosas/complicaciones
2.
Clin Exp Dermatol ; 47(4): 787-788, 2022 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-34856011

RESUMEN

We read with great interest the recently published article by Joos et al. on the successful use of baricitinib for cutaneous lupus erythematosus. The authors presented a heavily pretreated case of subacute cutaneous lupus erythematosus (SCLE) with almost complete clearance following 6 months of baricitinib therapy. We would like to add our experiences of baricitinib for SCLE in a patient with concomitant frontal fibrosing alopecia.


Asunto(s)
Liquen Plano , Lupus Eritematoso Cutáneo , Alopecia/complicaciones , Alopecia/tratamiento farmacológico , Azetidinas , Humanos , Liquen Plano/complicaciones , Liquen Plano/tratamiento farmacológico , Lupus Eritematoso Cutáneo/complicaciones , Lupus Eritematoso Cutáneo/tratamiento farmacológico , Purinas , Pirazoles , Sulfonamidas
3.
J Dtsch Dermatol Ges ; 20(12): 1581-1588, 2022 12.
Artículo en Inglés | MEDLINE | ID: mdl-36442137

RESUMEN

BACKGROUND AND OBJECTIVES: In recent years, considerable insight has been gained into the pathogenesis, diagnosis and treatment of cutaneous sarcomas, including atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS). Both entities have shown increasing incidence rates in the last decade. This study was initiated to evaluate how these new insights impact the number of diagnoses of AFX/PDS compared to other cutaneous sarcoma entities. PATIENTS AND METHODS: In a retrospective study of four German skin cancer centers, all histopathological reports of cutaneous sarcomas (AFX, PDS, dermatofibrosarcoma protuberans, cutaneous leiomyosarcoma, angiosarcoma, and Kaposi sarcoma) confirmed by board-certified dermatopathologists were analyzed during a time-period of seven years (2013-2019). Additionally, utilization of immunohistochemical markers (including pan-cytokeratin, S100, desmin, CD34, CD10, procollagen-1, CD99, CD14, and CD68) as an adjunct to diagnose AFX/PDS was recorded. RESULTS: Overall, 255 cutaneous sarcomas were included in the present study. The diagnosis of a cutaneous sarcoma has consequently risen from 2013 to 2019 (from 16 to 52 annual cases). The results of AFX/PDS revealed 4.6 times more diagnoses in 2019 than in 2013. Atypical fibroxanthoma represented the most common subtype, displaying 49.3 % of all diagnosed cutaneous sarcomas. Additionally, the increase of AFX/PDS was linked to the use of immunohistochemistry, with specific immunohistochemical markers used in 57.1 % of cases in 2013 compared to 100 % in 2019. CONCLUSIONS: This retrospective study of four German skin cancer centers demonstrates a substantial rise of AFX/PDS, possibly due to recently established diagnostic and terminology standards. This rise is probably linked to increased utilization of specific immunohistochemical markers. Atypical fibroxanthoma/PDS may be more common than previously thought and seems to represent the most frequent cutaneous sarcoma subtype.


Asunto(s)
Histiocitoma Fibroso Maligno , Sarcoma , Neoplasias Cutáneas , Humanos , Estudios Retrospectivos , Sarcoma/diagnóstico , Sarcoma/epidemiología , Neoplasias Cutáneas/diagnóstico , Neoplasias Cutáneas/epidemiología , Neoplasias Cutáneas/etiología , Histiocitoma Fibroso Maligno/diagnóstico , Inmunohistoquímica , Biomarcadores de Tumor/análisis , Diagnóstico Diferencial
4.
J Dtsch Dermatol Ges ; 20(12): 1581-1588, 2022 12.
Artículo en Inglés | MEDLINE | ID: mdl-36508370

RESUMEN

HINTERGRUND UND ZIELE: In den letzten Jahren konnten umfassende Erkenntnisse über die Pathogenese, Diagnostik und Behandlung von kutanen Sarkomen, insbesondere des atypischen Fibroxanthoms (AFX) und pleomorphen dermalen Sarkoms (PDS) gesammelt werden. Beide Entitäten zeigten innerhalb der letzten Dekade steigende Inzidenzraten. Die vorliegende Studie diente der Untersuchung, welchen Einfluss die neuen Erkenntnisse auf die Fallzahlen von AFX/PDS im Vergleich zu anderen Sarkom-Entitäten haben. PATIENTEN UND METHODIK: Diese retrospektive Studie wurde an vier deutschen Hauttumorzentren durchgeführt und alle von zertifizierten Dermatopathologen bestätigten histopathologischen Befunde von kutanen Sarkomen (AFX, PDS, Dermatofibrosarcoma protuberans, kutanes Leiomyosarkom, Angiosarkom und Kaposi-Sarkom) in einem Zeitraum von sieben Jahren (2013-2019) evaluiert. Zusätzlich wurde der Einsatz von immunhistochemischen Markern als diagnostische Hilfe (Panzytokeratin, S100, Desmin, CD34, CD10, Prokollagen-1, CD99, CD14 und CD68) erfasst. ERGEBNISSE: Insgesamt konnten 255 kutane Sarkome in die vorliegende Studie eingeschlossen werden. Die Zahl der kutanen Sarkome nahm kontinuierlich von 2013 bis 2019 zu (von 16 auf 52 Fälle im Jahr). Die Diagnose eines AFX/PDS konnte in 2019 4,6-mal häufiger als in 2013 gestellt werden. Das AFX stellte mit 49,3 % aller kutanen Sarkome den häufigsten Sarkom-Subtypen dar. Zusätzlich war der Anstieg von AFX/PDS mit dem Einsatz von Immunhistochemie assoziiert. Der Einsatz von spezifischen Immunhistochemischen Markern stieg von 57,1 % im Jahr 2013 auf 100 % in 2019. SCHLUSSFOLGERUNGEN: Diese retrospektive Studie von vier deutschen Hauttumorzentren demonstriert eine substanzielle Zunahme von AFX/PDS, wahrscheinlich infolge kürzlich etablierter beziehungsweise verbesserter diagnostischer und terminologischer Standards. Dieser Anstieg ist vermutlich mit dem vermehrten Einsatz von bestimmten immunhistochemischen Markern assoziiert. AFX/PDS treten wahrscheinlich häufiger auf als bisher vermutet und repräsentieren möglicherweise den häufigsten kutanen Sarkom-Subtyp.

13.
Dermatologie (Heidelb) ; 75(1): 15-21, 2024 Jan.
Artículo en Alemán | MEDLINE | ID: mdl-37962649

RESUMEN

Anorectal melanomas are a rare malignant type of cancer and pose a diagnostic challenge due to their hidden anatomical location. They are associated with nonspecific clinical symptoms and are therefore often misinterpreted as benign disease. The result is delayed diagnosis in the locally advanced or metastasized stage and an unfavorable prognosis. Given the overall low incidence of the tumor, no consensus guidelines for diagnosis or therapy are established either internationally or nationally at present. The present work intends to provide a comprehensive overview of the clinical aspects, diagnostics, and therapeutic approaches of anorectal melanoma based on the currently available literature.


Asunto(s)
Neoplasias del Ano , Melanoma , Neoplasias del Recto , Humanos , Melanoma/diagnóstico , Neoplasias del Recto/diagnóstico , Neoplasias del Ano/diagnóstico , Pronóstico , Radioterapia Adyuvante
14.
Dermatologie (Heidelb) ; 75(9): 729-732, 2024 Sep.
Artículo en Alemán | MEDLINE | ID: mdl-38717539

RESUMEN

Localized lymphedema of the genital region is a rare medical condition. It is named primary lymphedema if caused by a congenital malformation of the lymphatic system. Secondary lymphedemas might be induced by exogenous damage to lymphatic vessels as a result of surgical interventions, obesity, filariasis, radiotherapy or malignancy. We report a case of localized lymphedema of the genial region for which a previously unknown urothelial carcinoma turned out to be the underlying cause.


Asunto(s)
Linfedema , Humanos , Linfedema/patología , Linfedema/etiología , Masculino , Anciano , Neoplasias de la Vejiga Urinaria/complicaciones , Neoplasias de la Vejiga Urinaria/cirugía , Neoplasias de la Vejiga Urinaria/patología , Carcinoma de Células Transicionales/complicaciones , Carcinoma de Células Transicionales/cirugía , Carcinoma de Células Transicionales/patología , Carcinoma de Células Transicionales/diagnóstico
15.
Artículo en Alemán | MEDLINE | ID: mdl-39120755

RESUMEN

Mycosis fungoides (MF) is defined as the most common cutaneous T­cell lymphoma (CTCL). The bullous form is considered one of its numerous variants. Only a few cases of this rare entity have been described. We report the case of a man with an aggressive course of bullous MF, which led to lethal outcome within a few weeks due to a fulminant sepsis.

16.
Int J STD AIDS ; 33(5): 508-510, 2022 04.
Artículo en Inglés | MEDLINE | ID: mdl-35282716

RESUMEN

Tinea corporis is a common superficial dermatophytosis mostly located at the trunk and extremities. In contrast, tinea of the anogenital region is rare and predominantly occurs in tropical countries. In recent years, a distinctive variant of pubogenital tinea (PT) characterized by deep tissue infiltration and systemic symptoms has been reported, and transmission via sexual contacts has been hypothezised. In the majority of cases, a new genotype of Trichophyton mentagrophytes classified as T. mentagrophytes VII was detected as the causative pathogen. We report a case of PT caused by T. quinckeanum that experienced a strong inflammatory reaction following initiation of successful antifungal treatment with itraconazole.


Asunto(s)
Tiña , Trichophyton , Antifúngicos/uso terapéutico , Arthrodermataceae , Humanos , Itraconazol/uso terapéutico , Tiña/diagnóstico , Tiña/tratamiento farmacológico , Tiña/microbiología , Trichophyton/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA